Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Ropivacaine With Adjuncts for ACB and IPACK Block in TKA
NCT07509866Completed
- Sponsor
- Huazhong University of Science and Technology
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in postoperative pain comparing Liposomal Bupivacaine Group, Ropivacaine + Dexamethasone Group and Ropivacaine + Dexmedetomidine Group (3 arms). Primary endpoint: Total opioid consumption at 72 hours. Started Apr 2026; status: completed.
02
Drugs
liposomal bupivacaineropivacainedexamethasonedexmedetomidine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07509866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509866.